Shots:
- Samsung Bioepis has entered into a definitive agreement to grant Harrow exclusive commercial rights of its ophthalmology biosimilar portfolio incl. Byooviz, biosimilar to Lucentis (ranibizumab), & Opuviz, biosimilar to Eylea (aflibercept) in the US
- Byooviz has been available in the US through Biogen since its launch in Jun 2022. In Oct 2024, Biogen notified Samsung Bioepis of its decision to end their 2019 Deal in the US & Canada, & both companies are working on transferring commercialization rights for Byooviz & Opuviz back to Samsung Bioepis
- Harrow will handle US commercialization of Byooviz after the transfer of rights to Samsung Bioepis, which is expected to be completed by the end of 2025
Ref: Businesswire | Image: Samsung Bioepis & Harrow| Press Release
Related News:- Samsung Bioepis Collaborates with NIPRO to Commercialize Biosimilar Candidates in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
